Similarly, there were 24 and 15 cohorts in PrognoScan database, respectively, that showed CELF2 could serve as a predictor of favourable prognosis in breast and lung cancers (Supplementary Table 2). This evidence concerns the gene CELF2 and lung carcinoma.